Wendy Schilling
Internal Medicine · Ashland, ORNPI 1528047727
Payments from drug & device makers
Across 114 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$372
- CSL Behring$321
- AbbVie$221
- AstraZeneca$214
- Amgen$211
- Argenx US, Inc.$125
- plus $900 from 22 others
What the payments were for
- Speaking & faculty fees$120%
- Food & beverage$2,353100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 19 | $372 |
| CSL Behring | 17 | $321 |
| AbbVie | 10 | $221 |
| AstraZeneca(2 entities) | 11 | $214 |
| Amgen | 10 | $211 |
| Argenx US, Inc. | 5 | $125 |
| Johnson & Johnson | 5 | $91 |
| Sanofi | 4 | $86 |
| Si-bone, Inc. | 1 | $76 |
| Grifols USA, LLC | 3 | $67 |
| Genentech USA, Inc. | 3 | $64 |
| Novartis | 3 | $60 |
| Lundbeck LLC | 3 | $56 |
| GSK | 2 | $55 |
| Tanabe Pharma America, Inc. | 3 | $54 |
| Lilly USA, LLC | 2 | $37 |
| ITF Therapeutics LLC | 1 | $33 |
| Eisai Inc. | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Neurocrine Biosciences, Inc. | 2 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Davol Inc. | 1 | $13 |
| Acorda Therapeutics, Inc | 1 | $12 |
How this compares
$2,364 in reported general payments places this provider in the 90th percentile of 1,363 internal medicine providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $82,124 |
| OzempicSemaglutide | 13 | $24,834 |
| OxycontinOxycodone Hcl | 13 | $3,551 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,114 |
| SynthroidLevothyroxine Sodium | 22 | $1,998 |
| Olmesartan Medoxomil | 12 | $1,781 |
| Levothyroxine Sodium | 130 | $1,631 |
| Gabapentin | 53 | $1,576 |
| Potassium Chloride | 51 | $1,229 |
| Estradiol | 34 | $1,199 |
| Tamsulosin Hcl | 33 | $1,154 |
| Atorvastatin Calcium | 82 | $1,147 |
| Lisinopril | 68 | $847 |
| Quetiapine Fumarate | 23 | $814 |
| Oxycodone Hcl | 26 | $778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $221 | $1,99822 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,631130 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $31 | $28616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 internal medicine providers in Oregon.
Other internal medicine in Ashland
- Stephen SpurgeonPortland$8.6M
- Drissana TranSalem$4.8M
- James BergtholdPortland$4.7M
- Stephen FortmannPortland$3.3M
- Maryann ConradPortland$2.7M
- Brian CurtisCorvallis$2.4M
- Jennifer SaultzPortland$1.9M
- Elizabeth LilesHillsboro$1.9M
- Marc UemuraEugene$1.6M
- Michael ChenStayton$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.